and no wonder sanifi is so keen on it. little's look at the cofounder and ceo of regeneron, welcome back to "mad money," len. >> thank you for having us. >> i'm look at the research. december 11, 2013, the survey continued limited upside on eylea. the stock is at $274 when they did this. is there a continued limited upside for eylea? >> we think that eylea has lots of opportunities to grow. we think it can grow based on demographics. more people getting old ever. we think it the grow geographically. we think it can grow by new indications. we have submitted it to the fda. if we're fortunate enough to get approval we expect the action on that in august of this year. we can grow by additional indications. we have more indications to submit. so i don't think this product has matured just yet. >> how about this anti-cholesterol drug that may be tolerated for people who cannot -- who cannot tolerate the usual statins? you're getting closer and closer on this one. do you think 3 to $5 billion i'm wrong? >> we don't like to specu